ALX Oncology appoints Alan Sandler to Board; Pons and Randolph resign from Board

ALX ONCOLOGY HOLDINGS INC

Alan Sandler, M.D., appointed to Board effective Aug 5, 2024; receives initial option for 40,400 shares vesting over 36 months.
Jaume Pons (President/CSO) and Sophia Randolph (CMO) resign from Board to focus on executive roles; no disagreement.
Board size decreased; now 4 of 5 directors are independent, resolving prior non-compliance with Nasdaq Rule 5605(a)(2).

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Sophia Randolph

Director

ALXO · ALX ONCOLOGY HOLDINGS INC

Effective: 2024-08-05
Filed: August 6, 2024, 7:59 PM ET

In addition, on August 5, 2024, Jaume Pons, Ph.D., and Sophia Randolph, M.D., Ph.D., resigned as members of the Company’s Board.

Appointed

Alan Sandler

Director

ALXO · ALX ONCOLOGY HOLDINGS INC

Effective: 2024-08-05
Filed: August 6, 2024, 7:59 PM ET

On August 5, 2024, the Board of Directors of ALX Oncology Holdings Inc. (the “Company”) appointed Alan Sandler, M.D. to serve as a Class III director of the Board of Directors of the Company (the “Board”) for a term expiring at the 2026 annual meeting of stockholders

Departed

Jaume Pons

Director

ALXO · ALX ONCOLOGY HOLDINGS INC

Effective: 2024-08-05
Filed: August 6, 2024, 7:59 PM ET

In addition, on August 5, 2024, Jaume Pons, Ph.D., and Sophia Randolph, M.D., Ph.D., resigned as members of the Company’s Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sophia Randolph resigned as Director at ALX ONCOLOGY HOLDINGS INC.

Action: resigned
Role: Director

Exact text from the filing

In addition, on August 5, 2024, Jaume Pons, Ph.D., and Sophia Randolph, M.D., Ph.D., resigned as members of the Company’s Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Alan Sandler was appointed as Director at ALX ONCOLOGY HOLDINGS INC.

Action: appointed
Role: Director

Exact text from the filing

On August 5, 2024, the Board of Directors of ALX Oncology Holdings Inc. (the “Company”) appointed Alan Sandler, M.D. to serve as a Class III director of the Board of Directors of the Company (the “Board”) for a term expiring at the 2026 annual meeting of stockholders

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jaume Pons resigned as Director at ALX ONCOLOGY HOLDINGS INC.

Action: resigned
Role: Director

Exact text from the filing

In addition, on August 5, 2024, Jaume Pons, Ph.D., and Sophia Randolph, M.D., Ph.D., resigned as members of the Company’s Board.

View on SEC.gov

ALX ONCOLOGY HOLDINGS INC filing history →

Source: SEC EDGAR

accession 0000950170-24-091938

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.